.png){kind=small}
.png){kind=small}
BackTable / OBGYN / Podcast / Episode #45
RhoGAM’s Role in Pregnancy: Facts & Controversies
with Dr. Matt Reeves
This episode of BackTable OBGYN features Dr. Matt Reeves, a seasoned OBGYN and CEO/Founder of the DuPont Clinic, and host Dr. Amy Park as they discuss the use of Rh immune globulin (RhoGAM) in pregnancy.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2024, January 23). Ep. 45 – RhoGAM’s Role in Pregnancy: Facts & Controversies [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
RhoGAM is traditionally administered to Rh- women at 28 weeks gestation, within 72 hours of birth, and frequently after an abortion in order to prevent Rhesus alloimmunization in future pregnancies. However, with recent data showing negligible Rh- blood cell exposure in early pregnancy terminations, the need for RhoGAM in such cases is being questioned. Additionally, considering the scarcity of RhoGAM and the reality of smaller family sizes globally, the importance of RhoGAM in Rh alloimmunization prevention might not be as significant as previously thought. However, limited evidence and ingrained medical practices may cause the transition to be slow.
Timestamps
00:00 - Introduction
03:09 - Understanding RhoGAM: Origin and Development
06:06 - The Science Behind RhoGAM and Its Role in Pregnancy
08:13 - The Controversy and Debate Around RhoGAM Usage
11:52 - The Impact of RhoGAM on Public Health and Medical Practice
15:25 - The Future of RhoGAM: Perspectives and Predictions
29:24 - Closing Thoughts and Further Resources
Resources
Horvath, S., Goyal, V., Traxler, S., & Prager, S. (2022). Society of Family Planning committee consensus on Rh testing in early pregnancy. Contraception, 114, 1–5. https://doi.org/10.1016/j.contraception.2022.07.002
https://pubmed.ncbi.nlm.nih.gov/35872236/
Horvath S, Huang Z, Koelper NC, et al. Induced Abortion and the Risk of Rh Sensitization. JAMA. 2023;330(12):1167–1174. doi:10.1001/jama.2023.16953
https://pubmed.ncbi.nlm.nih.gov/37750879/
Transcript Preview
[Dr. Matt Reeves]
Most abortion providers in the country would almost force that patient to have RhoGAM. It really wasn't even a discussion, and there was no shared decision-making about, "Is it worth it for me to give RhoGAM?" When you throw in there how it's made, I think a lot of patients might think twice about it. It's not an entirely benign substance.
The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
Articles
Rethinking RhoGAM Administration Guidelines
RhoGAM & Its Role in Pregnancy & Miscarriage
Topics
